On May 27, 2022, the U.S. Food and Drug Administration (FDA) approved Amneal's biologics license application for Fylnetra™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta® (Agmen).
For more information, read Amneal's announcement.
Posted 5/31/2022
